NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. as Head of Ophthalmic Drug Development
04. Oktober 2011 07:00 ET
|
NovaBay Pharmaceuticals, Inc.
Former Alcon Executive With Significant Experience in Ophthalmic Drug Development to Oversee NovaBay's Program for Viral Conjunctivitis (Pink Eye)
EMERYVILLE, Calif., Oct. 4, 2011 (GLOBE NEWSWIRE)...
NovaBay Pharmaceuticals Names Russell A. Hoon as Vice President of Its Advanced Wound Care Business Unit
28. September 2011 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
Executive With Three Decades of Experience in Medical Products Industry to Oversee NovaBay's Commercial Launch of NeutroPhase®
EMERYVILLE, Calif., Sept. 28, 2011 (GLOBE NEWSWIRE) --...
NovaBay Pharmaceuticals to Present At the LD MICRO Invitational Conference
21. September 2011 13:53 ET
|
NovaBay Pharmaceuticals, Inc.
Management to Present at 1:00 PM PDT / 4:00 PM EDT on September 22, 2011
EMERYVILLE, Calif., Sept. 21, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage...
NovaBay Pharmaceuticals' Reports Positive Results in Sinus Infection Study
12. September 2011 12:39 ET
|
NovaBay Pharmaceuticals, Inc.
Study Results Were Presented at the American Rhinologic Society Meeting on September 10, 2011
EMERYVILLE, Calif., Sept. 12, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE...
NovaBay Pharmaceuticals Highlighted in Cataract & Refractive Surgery Today
25. August 2011 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
Article Outlines Activity of Aganocide Compounds Against Ophthalmic Pathogens
EMERYVILLE, Calif., Aug. 25, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSEAmex:NBY), a...
NovaBay Pharmaceuticals to Present at The 2011 Southern California Investor Conference
24. August 2011 16:00 ET
|
NovaBay Pharmaceuticals, Inc.
Webcast to Begin at 10:30 AM PDT, 1:30 PM EDT on August 29, 2011
EMERYVILLE, Calif., Aug. 24, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage...
NovaBay Pharmaceuticals Reports Second Quarter Financial Results
10. August 2011 08:15 ET
|
NovaBay Pharmaceuticals, Inc.
Three Phase 2 Programs in Dermatology, Urology, and Ophthalmology Advancing
EMERYVILLE, Calif., Aug. 10, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a...
NovaBay Pharmaceuticals Provides Business Update
11. Juli 2011 07:00 ET
|
NovaBay Pharmaceuticals, Inc.
Reports on Progress in Its Four Business Units and Use of Cash, Including Proceeds From Recent Cash Infusion
EMERYVILLE, Calif., July 11, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc....
NovaBay Pharmaceuticals Announces the Closing of Its $5.2 Million Registered Direct Offering of Common Stock and Warrants
05. Juli 2011 13:06 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 5, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY) announced today that it has closed its previously announced registered direct offering for the sale...
NovaBay Pharmaceuticals, Inc. Announces Pricing of a $5.2 Million Registered Direct Offering of Common Stock and Warrants
29. Juni 2011 09:05 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 29, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex:NBY) announced that it has entered into definitive subscription agreements with investors, including a...